Drs Banu Arun and Avan J. Armaghani discuss the evolving treatment landscape of targeted therapy for advanced and metastatic breast cancer, including risk factors, quality of life, and treatment access.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982651). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Breast Cancer https://emedicine.medscape.com/article/1947145-overview

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview#:~:text=Metastatic%20Breast%20Cancer-,Practice%20Essentials,20%25%20of%20invasive%20breast%20cancers.

Personalized Medicine https://www.genome.gov/genetics-glossary/Personalized-Medicine

Emerging Digital Technologies in Cancer Treatment, Prevention, and Control https://pubmed.ncbi.nlm.nih.gov/34850933/

Introduction to Antibody-drug Conjugates https://pubmed.ncbi.nlm.nih.gov/34842621/

Antibody-drug Conjugates and Subgroups of Advanced and Metastatic Breast Cancer: Strategies, Resistance, Emerging Data https://www.medscape.com/viewarticle/982644 

Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive Metastatic Breast Cancer (CLEOPATRA): End-of-study Results From a Double-blind, Randomised, Placebo-controlled, Phase 3 Study https://pubmed.ncbi.nlm.nih.gov/32171426/

Trastuzumab Deruxtecan in Previously Treated HER2-positive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/31825192/

Trastuzumab Deruxtecan Versus Trastuzumab Emtansine in Patients With HER2-positive Metastatic Breast Cancer: Updated Results From DESTINY-Breast03, a Randomised, Open-label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/36495879/

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) https://clinicaltrials.gov/ct2/show/NCT04784715

Targeting HER3 for Cancer Treatment: A New Horizon for an Old Target https://pubmed.ncbi.nlm.nih.gov/36764093/

A Review of Triple-negative Breast Cancer https://www.medscape.com/viewarticle/727195_4

Tucatinib Versus Placebo Added to Trastuzumab and Capecitabine for Patients With Pretreated HER2+ Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis https://pubmed.ncbi.nlm.nih.gov/34954044/

Progression-free Survival: What Does It Mean for Psychological Well-being or Quality of Life? https://www.ncbi.nlm.nih.gov/books/NBK137763/

A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04) https://clinicaltrials.gov/ct2/show/NCT04539938

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) https://clinicaltrials.gov/ct2/show/NCT05132582

Tyrosine Kinase Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK563322/